Promising new combo therapy for adult leukemia patients

This study is for adults aged 14 to 60 with newly diagnosed Ph-negative acute lymphoblastic leukemia (ALL), a fast-growing blood cancer. Researchers are testing a treatment plan that combines a pediatric-style chemotherapy with the targeted drug venetoclax and immunotherapy. The goal is to see if this approach improves how long patients stay cancer-free and increases remission rates. Participants will receive several phases of treatment over time, and the study will monitor side effects and overall survival.